Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 and over~* Clinical status according to the WHO scale - 6, 7, 8 and 9 points.~* Verified respiratory infection COVID-19 by real-time PCR (quantitative)~* Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:~  * women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);~ * men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility)~* Availability of signed and dated informed consent of the patient to participate in the study.~Exclusion Criteria:~* Clinical status according to the WHO scale - 1, 2, 3, 4 and 5 points.~* Increased risk of bleeding:~  * extensive bleeding at the present time;~ * intracranial (including subarachnoid) hemorrhage at the present time.~* Lactation, pregnancy~* Known hypersensitivity to Fortelyzin®.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
- Placebo control (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).